H.C. Wainwright initiated coverage of Pharvaris (PHVS) with a Buy rating and $60 price target The company’s lead asset deucrictibant is the only oral bradykinin B2 receptor antagonist in development across both on-demand and prophylaxis settings, the analyst tells investors in a research note. The firm says deucrictibant is positioned to set a new standard in hereditary angioedema on-demand and prophylaxis.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris upgraded to Neutral from Underperform at BofA
- BofA upgrades Pharvaris to Neutral on potential label expansion
- Pharvaris Secures Registration Rights Agreement with General Atlantic
- Pharvaris Advances Clinical Pipeline with Strong Financials
- Pharvaris’ Strategic Advancements and Financial Strength Bolster Buy Rating